Business Wire

1E

11.5.2021 16:37:09 CEST | Business Wire | Press release

Share
1E Challenges DEM Market to Deliver More, Launching New Unified eXperience Management Category

1E , innovators in endpoint management, today announced Unified eXperience Management (UXM) , a new category that seeks to address the siloed approach inherent in tools in the Digital Experience Monitoring (DEM) space.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210511005842/en/

Due to the relative immaturity of the Digital Experience Management category, most tooling is focused on identifying and reporting on the scale of the problem, scoring, and issue identification. These tools create analytics silos that give insight, but are uncoupled from the automation technology that can actually improve end-user experience at an enterprise scale. Meanwhile, employees are becoming increasingly more frustrated, with 56% feeling dissatisfied with their IT experience . Organizations looking to improve the digital experience of all their employees need to move beyond analytics and embrace automation to resolve these issues.

Furthermore, this siloed approach of today’s DEM solutions neglects the substantial investment most large organizations have made into platforms like ServiceNow and Microsoft. The industry needs a solution that can leverage these investments to be part of the solution rather than ignore them.

1E is introducing the UXM category in response to these issues that unifies Digital Experience Monitoring with all the other aspects of IT required to positively impact the user’s experience. Unified eXperience Management comprises Experience Monitoring, Employee Engagement, Diagnostic and Remediation tooling, and Configuration Policy to ensure that once an issue is fixed on one machine it is applied to all machines on an ongoing basis. Deep and rich integration with service desk and UEM platforms like ServiceNow and Microsoft Endpoint Manager enable IT workers dealing with incidents to have access to insights and a shared library of fixes to ensure that end-user issues are dealt with in real-time.

“If a Digital Experience initiative can identify experience issues but has no clear line of sight to remediating them, it will deliver zero value; No employee ever wished IT had a better analytics solution,” said Sumir Karayi, CEO and founder of 1E. “They want less frustrating experiences, they want fewer disruptions. For this, IT needs to take a step beyond analytics that identifies issues, to an initiative that leverages automation to predict and improve experiences. That is how we view Unified eXperience Management -- proactive, real time, holistic action across all endpoints.”

To accompany the launch of the category, 1E’s Product Chief Technologist, Bogdan Udrea, will host a webinar exploring UXM and how it can help organizations enable a modern, hybrid workplace on May 18 at 11 a.m. ET. To attend, please visit: https://info.1e.com/webinar-go-beyond-digital-experience-management-what-is-uxm

This coincides with the latest release of 1E Tachyon , which brings new UXM capabilities to market. Tachyon 5.2 contains a unified device view that expedites troubleshooting and remediation of an endpoint on a single pane of glass. The latest release also introduces a new persona management capability, allowing IT to better understand the needs and experience challenges of different cohorts of employees.

Product Marketing Director, Michael Wright, will be launching Tachyon 5.2 on May 20th at 11am ET. To attend the launch event, please visit: https://info.1e.com/launch-showcase-tachyon-5.2-discover-complete-device-visibility

WFA Research: https://www.1e.com/wfa-research-2021/

About 1E

1E the innovators in endpoint management that supports the work from anywhere enterprise, so employees are secure, supported, and productive wherever they want to be. The 1E Tachyon Platform provides real-time diagnosis, remediation and automation that fixes issues, fast and without interruption. It puts employees in control, through self-service, self-heal and sentiment monitoring to understand how they really feel and reduces help desk calls and ultimately costs. That’s why more than 1,700 organizations in 42 countries trust 1E to help them manage 14 million endpoints seamlessly. For more information, visit www.1E.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye